Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5394 - Detection of Targetable Kinase Fusions in 7260 patients in an integrated Cancer System

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Ankur Parikh

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

A. Parikh1, S.M. Ali2, A. MORAN3, P. Crilley4, A.B. Schrock5, A. Tan6, P. Reddy2, V.A. Miller7, J.S. Ross8, S. Zook3, R.H. Alvarez3, M. Markman9

Author affiliations

  • 1 Medical Oncology, Cancer Treatment Centers of America, 19124 - Philadelphia/US
  • 2 Oncology, Foundation Medicine, Boston/US
  • 3 Medical Oncology, Cancer Treatment Centers of America, 30265 - Newnan/US
  • 4 Medical Oncology, Cancer Treatment Centers of America, 65 - Philadelphia/US
  • 5 Genetics, Foundation Medicine, Inc., MA 02141 - Cambridge/US
  • 6 Medical Oncology, Cancer Treatment Centers of America, Goodyear/US
  • 7 Genetics, Foundation Medicine, Inc., Cambridge/US
  • 8 Pathology Group, Foundation Medicine Inc., Cambridge/US
  • 9 Medical Oncology, Cancer Treatment Centers of America, Philadelphia/US
More

Resources

Abstract 5394

Background

Kinase fusions (KF), such as those involving ALK, are eminently targetable genomic alterations (GA) in lung and other cancers, the latter suggested by early clinical evidence (PMID: 29079636). We undertook a review of 7260 patient samples from a tertiary cancer care-focused network of five hospitals assayed with comprehensive genomic profiling (CGP).

Methods

Hybrid capture based CGP was performed on 7260 advanced cancer cases (12/2012-2/2018), with assessment of at least 186 genes (intronic baiting for at least 14) in tissue, and 62 genes (intronic baiting for 6) in circulating tumor DNA samples. Tumor mutational burden (TMB) was determined up to 1.2 Mbp of sequenced DNA.

Results

77/7260 (1%) samples in this series harbored KF. Patients (pts) with KF+ tumors had a median age of 53 years vs. 56 years in the overall population. The TMB in KF+ cases was 3.51 mut/Mb vs. 4.39 mut/Mb for all cases. KF were found in 55 lung (71%) and 22 (29%) non-lung samples. Of KF+ cases, 71% were non-small cell lung cancer, and the remainder were sarcoma (5%), breast cancer (4%), thyroid (4%), cancer of unknown primary (4%), pancreatic (3%), colorectal (3%) and others (1% each). Of KF+ non-lung cases, 39% had BRAF fusions, 30% had ALK fusions, 26% had RET fusions, and 4% had ROS1 fusions. One KF+ sarcoma pt received matched targeted therapy with ALK inhibitors including ceritinib and crizotinib. More recently, in 2017 samples alone, 42% (10/24) of KF+ cases were non-lung.

Conclusions

Greater access to CGP has led to increased detection of advanced cancer patients with tumors harboring KF, particularly those with non-lung cancers. The low frequency of the latter is a challenge for clinical investigation. As such, innovative solutions such as basket trial for kinase inhibitors are needed, which may be feasible in an integrated cancer care system with high patient volume.

Clinical trial identification

Legal entity responsible for the study

Ankur Parikh.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

A. Parikh: Consultant: Foundation Medicine, Inc (FMI). S.M. Ali, A.B. Schrock, P. Reddy, V.A. Miller, J.S. Ross: Employee and equity interest: FMI. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings